ERBB2 and breast carcinoma: In a HER2-positive (IHC 3+) breast cancer cell line (SK-BR-3) and trastuzumab-resistant breast cancer cell line (UACC-893), SYD985 and T-DM1 demonstrated similar potencies [42].